Evolution of systemic therapy of advanced hepatocellular carcinoma

被引：50
作者：
Yau, Thomas [1 ]
Chan, Pierre [1 ]
Epstein, Richard [1 ]
Poon, Ronnie T. [2 ]
机构：
[1] Queen Mary Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China
[2] Queen Mary Hosp, Dept Surg, Hong Kong, Hong Kong, Peoples R China
来源：
WORLD JOURNAL OF GASTROENTEROLOGY | 2008年 / 14卷 / 42期
关键词：
Advanced hepatocellular carcinoma; Chemotherapy; Doxorubicin; Sorafenib;
D O I：
10.3748/wjg.14.6437
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Hepatocellular carcinoma (HCC) commonly occurs in hepatitis B endemic areas, especially in Asian countries. HCC is highly refractory to cytotoxic chemotherapy. This resistance is partly related to its tumor biology, pharmacokinetic properties, and both intrinsic and acquired drug resistance. There is no convincing evidence thus far that systemic chemotherapy improves overall survival in advanced HCC patients. Other systemic approaches, such as hormonal therapy and immunotherapy, have also disappointing results. Recently, encouraging results have been shown in using sorafenib in the treatment of advanced HCC patients. In this review, we concisely summarize the evolution of developments in the systemic therapy of advanced HCC. (c) 2008 The WIG Press. All rights reserved.
引用
收藏
页码：6437 / 6441
页数：5
相关论文
共 50 条
  • [41] Liver regeneration: From myth to mechanism
    Taub, R
    [J]. NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2004, 5 (10) : 836 - 847
  • [42] Somatostatin receptor in human hepatocellular carcinomas: Biological, patient and tumor characteristics
    Verhoef, C.
    Van Dekken, H.
    Hofland, L. J.
    Zondervan, P. E.
    De Wilt, J. H. W.
    Van Marion, R.
    De Man, R. A.
    IJzermans, J. N. M.
    Van Eijck, C. H. J.
    [J]. DIGESTIVE SURGERY, 2008, 25 (01) : 21 - 26
  • [43] Watanuki A, 2002, ANTICANCER RES, V22, P1113
  • [44] BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
    Wilhelm, SM
    Carter, C
    Tang, LY
    Wilkie, D
    McNabola, A
    Rong, H
    Chen, C
    Zhang, XM
    Vincent, P
    McHugh, M
    Cao, YC
    Shujath, J
    Gawlak, S
    Eveleigh, D
    Rowley, B
    Liu, L
    Adnane, L
    Lynch, M
    Auclair, D
    Taylor, I
    Gedrich, R
    Voznesensky, A
    Riedl, B
    Post, LE
    Bollag, G
    Trail, PA
    [J]. CANCER RESEARCH, 2004, 64 (19) : 7099 - 7109
  • [45] Efficacy and tolerability of low-dose thalidomide as first-line systemic treatment of patients with advanced hepatocellular carcinoma
    Yau, Thomas
    Chan, Pierre
    Wong, Hilda
    Ng, Kelvin K.
    Chok, Siu-Ho
    Cheung, Tan-To
    Lam, Vincent
    Epstein, Richard J.
    Fan, Sheung-Tat
    Poon, Ronnie T. P.
    [J]. ONCOLOGY, 2007, 72 : 67 - 71
  • [46] A randomized phase III study of doxorubicin versus cisplatin/interferon α-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma
    Yeo, W
    Mok, TS
    Zee, B
    Leung, TWT
    Lai, PBS
    Lau, WY
    Koh, J
    Mo, FKF
    Yu, SCH
    T Chan, A
    Hui, P
    Ma, B
    Lam, KC
    Ho, WM
    Wong, HT
    Tang, A
    Johnson, PJ
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (20): : 1532 - 1538
  • [47] A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma
    Yuen, MF
    Poon, RTP
    Lai, CL
    Fan, ST
    Lo, CM
    Wong, KW
    Wong, WM
    Wong, BCY
    [J]. HEPATOLOGY, 2002, 36 (03) : 687 - 691
  • [48] Systemic therapy of advanced hepatocellular carcinoma: How hopeful should we be?
    Zhu, Andrew X.
    [J]. ONCOLOGIST, 2006, 11 (07) : 790 - 800
  • [49] A phase II study of epirubicin and thalidomide in unresectable or metastatic hepatocellular carcinoma
    Zhu, AX
    Fuchs, CS
    Clark, JW
    Muzikansky, A
    Taylor, K
    Sheehan, S
    Tam, K
    Yung, E
    Kulke, MH
    Ryan, DP
    [J]. ONCOLOGIST, 2005, 10 (06) : 392 - 398
  • [50] 1998, LANCET, V352, P17
12345